Celecoxib (Celebrex) is a selective COX-2 inhibitor — an NSAID that preferentially blocks the cyclooxygenase-2 enzyme responsible for inflammation and pain while sparing COX-1, which protects the stomach lining. This selectivity results in significantly less gastrointestinal toxicity than nonselective NSAIDs like ibuprofen or naproxen, though GI risk is not eliminated. Cardiovascular risk (heart attack, stroke) is similar to other NSAIDs. A sulfonamide moiety in its structure warrants consideration in patients with sulfonamide allergies. It is used for osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain, and primary dysmenorrhea.
Celecoxib
Uses & FDA Indications
Celecoxib is FDA-approved for the relief of signs and symptoms of osteoarthritis and rheumatoid arthritis in adults, juvenile rheumatoid arthritis in patients 2 years and older, management of acute pain in adults, treatment of primary dysmenorrhea (painful menstrual periods), and relief of signs and symptoms of ankylosing spondylitis.
Celecoxib was also approved as an adjunct to standard care for familial adenomatous polyposis (FAP), a hereditary condition predisposing to colorectal cancer, though this application has become less common in clinical practice as the benefit-risk balance requires careful individual assessment.
Off-label uses include management of gout flares and other inflammatory arthropathies. Like all NSAIDs, celecoxib should be used at the lowest effective dose for the shortest duration consistent with treatment goals.
How It Works
Celecoxib selectively inhibits cyclooxygenase-2 (COX-2), the inducible isoform of cyclooxygenase that is upregulated at sites of inflammation, injury, and fever. COX-2 catalyzes the conversion of arachidonic acid to prostaglandins and thromboxanes that sensitize pain receptors, promote vasodilation, and mediate the inflammatory cascade.
The key distinction from nonselective NSAIDs (ibuprofen, naproxen, aspirin) is that celecoxib largely spares COX-1 — the constitutive isoform that maintains gastric mucosal protection, platelet aggregation (via thromboxane A2), and renal blood flow. By preserving COX-1 activity in the gastric mucosa, celecoxib maintains the protective prostaglandin E2 and prostaglandin I2 production that prevents ulceration — the primary mechanism by which nonselective NSAIDs cause peptic ulcers.
The cardiovascular trade-off of COX-2 selectivity: COX-2 is also the primary source of vascular prostacyclin (PGI2), a potent vasodilator and platelet aggregation inhibitor produced by endothelial cells. By selectively inhibiting COX-2, celecoxib reduces prostacyclin production without equally reducing thromboxane A2 (which is COX-1-derived from platelets), potentially tipping the balance toward a prothrombotic state. This is the proposed mechanism underlying the cardiovascular risk of COX-2 selective agents — a risk that the PRECISION trial found to be comparable to that of naproxen and ibuprofen at usual doses.
FDA BOXED WARNING: Celecoxib and all NSAIDs carry a boxed warning for increased risk of serious cardiovascular thrombotic events including myocardial infarction and stroke, which can be fatal. Risk may occur early in treatment and increases with duration of use. Celecoxib is contraindicated in the setting of coronary artery bypass graft (CABG) surgery. A separate boxed warning covers serious gastrointestinal adverse events including bleeding, ulceration, and perforation.
Side Effects
Common
- Abdominal pain, dyspepsia, nausea — lower frequency than nonselective NSAIDs but not absent
- Diarrhea
- Headache, dizziness
- Peripheral edema — fluid retention; can exacerbate heart failure and hypertension
- Hypertension — all NSAIDs elevate blood pressure; celecoxib has similar BP effect to nonselective NSAIDs
- Upper respiratory tract infection symptoms
Serious
- Cardiovascular events — heart attack, stroke; risk increases with longer use and in patients with existing cardiovascular disease
- Gastrointestinal bleeding and perforation — reduced but not eliminated compared to nonselective NSAIDs
- Acute kidney injury — NSAIDs reduce renal prostaglandin production needed for maintaining renal blood flow, particularly in volume-depleted patients or those with pre-existing renal impairment
- Hepatotoxicity — rare but reported; monitor liver function in patients on long-term therapy
- Serious skin reactions — Stevens-Johnson syndrome, toxic epidermal necrolysis; rare
Drug Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| Anticoagulants (warfarin, apixaban, rivaroxaban) | Celecoxib inhibits CYP2C9, which metabolizes warfarin. Warfarin levels and anticoagulant effect may increase. Even with direct oral anticoagulants (DOACs), concurrent NSAID use raises bleeding risk at mucosal surfaces. | High — monitor INR closely if warfarin; avoid combination when possible; use with caution with DOACs |
| Antihypertensives (ACE inhibitors, ARBs, diuretics) | NSAIDs reduce prostaglandin-mediated vasodilation and sodium excretion, blunting the effect of antihypertensives and diuretics. Triple combination with ACEI/ARB + diuretic + NSAID significantly increases acute kidney injury risk. | High — monitor blood pressure and renal function; avoid triple combination ("triple whammy") |
| Aspirin (even low-dose) | Concurrent aspirin eliminates most of celecoxib's GI safety advantage by restoring COX-1 inhibition in the gastric mucosa. GI bleeding risk increases substantially. | Moderate-High — consider gastroprotective agent (PPI) if both must be used |
| Lithium | NSAIDs reduce renal lithium clearance, increasing lithium blood levels and risk of toxicity. | High — monitor lithium levels closely; consider dose adjustment |
| Fluconazole (CYP2C9 inhibitor) | Fluconazole inhibits CYP2C9, reducing celecoxib metabolism and approximately doubling celecoxib plasma concentrations. | Moderate — reduce celecoxib dose when starting fluconazole; monitor for NSAID toxicity |
Warnings & Contraindications
Contraindications
- Known hypersensitivity to celecoxib, sulfonamides, aspirin, or other NSAIDs
- History of asthma, urticaria, or allergic-type reactions to aspirin or other NSAIDs (aspirin-exacerbated respiratory disease)
- Use in the setting of coronary artery bypass graft (CABG) surgery
- Third trimester of pregnancy — NSAIDs can cause premature closure of the ductus arteriosus
Cardiovascular Risk
All NSAIDs, including celecoxib, increase the risk of serious cardiovascular thrombotic events. The risk appears to be dose-dependent and duration-dependent. Patients with established cardiovascular disease or risk factors for cardiovascular disease are at greater risk. The PRECISION trial (2016) found celecoxib was non-inferior to ibuprofen and naproxen in cardiovascular risk at commonly used doses, though this does not eliminate the risk compared to no NSAID use.
Sulfonamide Structure
Celecoxib contains a sulfonamide moiety that differs structurally from sulfonamide antibiotics. Current pharmacological evidence suggests true cross-reactivity with sulfonamide antibiotic allergy is unlikely, but the prescribing information lists sulfonamide allergy as a precaution. Patients with a history of severe reactions to sulfonamide antibiotics should use celecoxib with caution and under medical supervision.
Pregnancy
Use of NSAIDs including celecoxib at 20 weeks gestation or later may cause fetal renal dysfunction leading to oligohydramnios (low amniotic fluid) and potentially limb contractures or delayed lung maturation. Use at 30 weeks or later can cause premature closure of the ductus arteriosus. Avoid NSAID use in pregnancy unless clearly necessary, and avoid at 20 weeks or later if possible.
Check for cardiovascular and renal interaction risks with celecoxib.
Check Drug Interactions →Frequently Asked Questions
Is celecoxib safer than ibuprofen for the stomach?
Celecoxib carries a significantly lower risk of serious gastrointestinal events compared to nonselective NSAIDs like ibuprofen or naproxen at equivalent anti-inflammatory doses. COX-2 selectivity spares prostaglandin production in the gastric mucosa, which is primarily driven by COX-1 — preserving the protective mucus layer that nonselective NSAIDs disrupt. However, celecoxib does not eliminate GI risk entirely, particularly at higher doses or with prolonged use. Patients on low-dose aspirin alongside celecoxib lose most of the GI advantage since aspirin itself inhibits COX-1 in the gut.
Can patients with sulfa allergies take celecoxib?
Celecoxib contains a sulfonamide moiety in its chemical structure, which historically raised concern about cross-reactivity in patients with sulfonamide antibiotic allergies. Current evidence suggests that true pharmacological cross-reactivity between sulfonamide antibiotics and non-antibiotic sulfonamide-containing drugs like celecoxib is unlikely. However, the prescribing information lists sulfonamide allergy as a potential concern. Clinicians should assess each patient individually; those with a history of severe sulfonamide reactions warrant caution and careful monitoring.
Does celecoxib increase the risk of heart attack?
Yes, celecoxib carries a cardiovascular risk similar to other NSAIDs. All NSAIDs carry an FDA boxed warning for increased risk of serious cardiovascular events including heart attack and stroke. The PRECISION trial (2016) suggested celecoxib was non-inferior to ibuprofen and naproxen in cardiovascular risk at commonly prescribed doses. Celecoxib should be avoided in patients with established heart disease when possible and used at the lowest effective dose for the shortest necessary duration.